Blog
.jpg?width=1000&height=562&name=blog%20images%20(1).jpg)
How Human Tissue Testing Adds Commercial Value for Shareholders
Discover how human tissue testing enhances shareholder value, exploring its impact on drug discovery, precision medicine, and regenerative medicine within the life sciences industry.
03 September 2025
Current Landscape of FDA Stem Cell Approvals and Trials 2023-2025
Discover the latest advancements and FDA approvals in stem cell therapies, including iPSC and MSC treatments, reshaping the 2023-2025 clinical landscape.
02 September 2025
NIH Announces End to Exclusive Funding for Animal Model Research
NIH ends exclusive funding for animal model research, promoting New Approach Methodologies like organ-on-a-chip systems and human tissue testing.
18 August 2025
Revolutionizing IBD Research with Innovative In Vitro Models
Catch a glimpse into the future of inflammatory bowel disease (IBD) research with our ground breaking in vitro models.
11 August 2025
Upcoming Events
Conferences we will be attending, and webinars hosted by us
Come meet us on 6-8 October (in person) & 9-10 October (virtual) at Phoenix, AZ, USA. Venue: Arizona Biltmore
6-8 October (in person) & 9-10 October (virtual)
Come meet us 20-21 October 2025 / ACC Liverpool Exhibition Centre, UK / Booth #B07
21-22 October
Meet us at REPROCELL booth and learn about our CLINICAL STEM CELL SERVICES at the ISSCR International Symposium 2025 / 11-12 December / Boston MA, USA
11-12 December
Find out how our bespoke human tissue equivalents provide new research tools to advance discovery, aid testing in product development, and provide alternatives to the use of animals.
6 November
Corporate News
REPROCELL Launches ReproRegistry to Strengthen Access to Human Skin Samples for Research
REPROCELL launches ReproRegistry to improve research by providing better access to human skin samples for stem cell and drug discovery scientists.
21 August 2025
REPROCELL Unveils Cutting-Edge Neoantigen Detection Service to Propel Precision Cancer Immunotherapy
REPROCELL launches NeoSight, a neoantigen detection service for personalized cancer immunotherapy, offering high-confidence data and applications like cancer vaccines and biomarker discovery.
20 August 2025
REPROCELL and Durham University Researchers Develop iPSC-Derived Full-Thickness Human Skin Model
REPROCELL and Durham University develop a reliable, iPSC-derived full-thickness human skin model for research and therapeutic applications, enhancing drug discovery and regenerative medicine.
13 August 2025